Show Summary Details
Page of

Fast-acting fentanyl for breakthrough pain 

Fast-acting fentanyl for breakthrough pain
Chapter:
Fast-acting fentanyl for breakthrough pain
Author(s):

Andrew N. Davies

DOI:
10.1093/med/9780198834359.003.0057
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 February 2020

The landmark paper discussed in this chapter is ‘Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients’, published by Farrar et al. in 1998. It was the first description of a randomized controlled trial of a fast-acting fentanyl formulation for the management of breakthrough pain (i.e. oral transmucosal fentanyl citrate (OTFC)). Indeed, it was the first description of a randomized controlled trial of any of the so-called fast-acting fentanyl/rapid-onset opioid formulations for the management of breakthrough cancer pain. Moreover, the methodology employed in this study formed the basis for the methodology employed in many later studies (of other fast-acting fentanyl formulations).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.